Directorio

We are doing this study to find the most effective, safe dose of an experimental drug called SGR-1505 (the study drug). We want to know how well this study drug specifically targets a protein related to your B-cell cancer.

We are doing this study to determine whether specialty palliative care or primary palliative care is the best way to improve the quality of life and experience of patients and their caregivers.

The purpose of this research study is to determine whether data from mobile health technologies (such as smartwatches and smartphones) can be used to assess risk of prediabetes and type 2 diabetes. Using data from smartphones and smartwatches, we may be able to develop a noninvasive procedure for identifying patients who are at risk and should be tested for diabetes. Participants can earn up to $50. For more information about who can be in this study, please contact the study team at diabeteswatch2@duke.edu.

If you join the study, you will be asked to complete a survey that takes about 20 minutes. It will ask about how you made choices for your breast cancer treatment. In six months, when most treatment choices are finished, you will be asked to complete another survey that takes about 30 minutes. At the end of the second survey, you will be asked if you are willing to take part in an interview at the end of the study.

We are testing a new type of electrode and a special computer system that can read signals from the skin. The person in the study will wear these new electrodes on their feet.

We are doing this study to get more information about the safety and performance of the Signia® circular adapter and stapler (the study technology). This device is FDA-approved for use as a tool to connect or re-connect tissues after a surgery. We want to know how successful it is at promoting healing for people who have left sided colon, sigmoid, or rectal resections at Duke.

We are doing this study to find out if an investigational drug called RGN-259 Thymosin Beta 4 eye drops solution (the study drug) is a safe and effective option for the treatment of neurotrophic keratopathy.

We are doing this study to test the feasibility and acceptability of an experimental communication device. This device was invented by a team from the Duke Pratt School of Engineering and is intended to help people with dementia and their caregivers. We want to know if this tool can be used to help people with dementia who live at home with their families.